Italian Association of Clinical Endocrinologists (AME) Position Statement: Drug Therapy of Osteoporosis

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2016 Mar 13

PMID 26969462

Citations 22

Authors

F Vescini

R Attanasio

A Balestrieri

F Bandeira

S Bonadonna

V Camozzi

S Cassibba

R Cesareo

I Chiodini

C Maria Francucci

L Gianotti

F Grimaldi

R Guglielmi

B Madeo

C Marcocci

A Palermo

A Scillitani

E Vignali

V Rochira

M Zini

Affiliations

Soon will be listed here.

Abstract

Treatment of osteoporosis is aimed to prevent fragility fractures and to stabilize or increase bone mineral density. Several drugs with different efficacy and safety profiles are available. The long-term therapeutic strategy should be planned, and the initial treatment should be selected according to the individual site-specific fracture risk and the need to give the maximal protection when the fracture risk is highest (i.e. in the late life). The present consensus focused on the strategies for the treatment of postmenopausal osteoporosis taking into consideration all the drugs available for this purpose. A short revision of the literature about treatment of secondary osteoporosis due both to androgen deprivation therapy for prostate cancer and to aromatase inhibitors for breast cancer was also performed. Also premenopausal females and males with osteoporosis are frequently seen in endocrine settings. Finally particular attention was paid to the tailoring of treatment as well as to its duration.

Citing Articles

The essential role of combined calcium and vitamin D supplementation in the osteoporosis scenario in italy: Expert opinion paper.

Carugo S, Vescini F, Giusti A, Letizia Mauro G, Tafaro L, Festuccia F Arch Osteoporos. 2024; 19(1):99.

PMID: 39438361 PMC: 11496317. DOI: 10.1007/s11657-024-01451-x.

Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications.

Baldessari C, Pipitone S, Molinaro E, Cerma K, Fanelli M, Nasso C Cancers (Basel). 2023; 15(5).

PMID: 36900309 PMC: 10000416. DOI: 10.3390/cancers15051518.

Changes in the composition of gut and vaginal microbiota in patients with postmenopausal osteoporosis.

Yang X, Chang T, Yuan Q, Wei W, Wang P, Song X Front Immunol. 2022; 13:930244.

PMID: 36032115 PMC: 9411790. DOI: 10.3389/fimmu.2022.930244.

COVID-19 lockdown negatively impacted on adherence to denosumab therapy: incidence of non-traumatic fractures and role of telemedicine.

De Vincentis S, Domenici D, Ansaloni A, Boselli G, DAngelo G, Russo A J Endocrinol Invest. 2022; 45(10):1887-1897.

PMID: 35590044 PMC: 9119380. DOI: 10.1007/s40618-022-01820-8.

Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience.

Gagliardi I, Celico M, Gamberini M, Pontrelli M, Fortini M, Carnevale A Calcif Tissue Int. 2022; 111(1):56-65.

PMID: 35243531 PMC: 9232424. DOI: 10.1007/s00223-022-00963-3.

References

Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P . Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2012; 24(2):398-405. DOI: 10.1093/annonc/mds277. View

Snyder P, Peachey H, Hannoush P, Berlin J, Loh L, Holmes J . Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999; 84(6):1966-72. DOI: 10.1210/jcem.84.6.5741. View

Wark J, Bensen W, Recknor C, Ryabitseva O, Chiodo 3rd J, Mesenbrink P . Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporos Int. 2011; 23(2):503-12. DOI: 10.1007/s00198-011-1563-8. View

Whitaker M, Guo J, Kehoe T, Benson G . Bisphosphonates for osteoporosis--where do we go from here?. N Engl J Med. 2012; 366(22):2048-51. DOI: 10.1056/NEJMp1202619. View

Aapro M, Abrahamsson P, Body J, Coleman R, Colomer R, Costa L . Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2007; 19(3):420-32. DOI: 10.1093/annonc/mdm442. View

Hochberg M, Greenspan S, Wasnich R, Miller P, Thompson D, Ross P . Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002; 87(4):1586-92. DOI: 10.1210/jcem.87.4.8415. View

Heiss G, Wallace R, Anderson G, Aragaki A, Beresford S, Brzyski R . Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008; 299(9):1036-45. DOI: 10.1001/jama.299.9.1036. View

Middleton E, Steel S, Aye M, Doherty S . The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years. Osteoporos Int. 2011; 23(1):295-303. DOI: 10.1007/s00198-011-1547-8. View

Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tato L . Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res. 2005; 20(5):758-63. DOI: 10.1359/JBMR.041232. View

10.

Pinkerton J, Goldstein S . Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Menopause. 2010; 17(3):642-53. DOI: 10.1097/gme.0b013e3181c4f1d6. View

11.

Recker R, Lappe J, Davies K, Heaney R . Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res. 2000; 15(10):1965-73. DOI: 10.1359/jbmr.2000.15.10.1965. View

12.

Mortensen L, Charles P, Bekker P, Digennaro J, JOHNSTON Jr C . Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab. 1998; 83(2):396-402. DOI: 10.1210/jcem.83.2.4586. View

13.

Martinez-Morillo M, Grados D, Holgado S . Premenopausal osteoporosis: how to treat?. Reumatol Clin. 2011; 8(2):93-7. DOI: 10.1016/j.reuma.2011.05.011. View

14.

Watts N, Bilezikian J, Camacho P, Greenspan S, Harris S, Hodgson S . American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2011; 16 Suppl 3:1-37. PMC: 4876714. DOI: 10.4158/ep.16.s3.1. View

15.

Nikitovic M, Solomon D, Cadarette S . Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendations. Ther Adv Chronic Dis. 2012; 1(4):149-162. PMC: 3265538. DOI: 10.1177/2040622310376137. View

16.

Miller P, Jamal S, Evenepoel P, Eastell R, Boonen S . Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res. 2013; 28(10):2049-59. DOI: 10.1002/jbmr.2058. View

17.

Vahle J, Sato M, Long G, Young J, Francis P, Engelhardt J . Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002; 30(3):312-21. DOI: 10.1080/01926230252929882. View

18.

Kanis J, Johnell O, Black D, Downs Jr R, Sarkar S, Fuerst T . Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone. 2003; 33(3):293-300. DOI: 10.1016/s8756-3282(03)00200-x. View

19.

Delmas P, Li Z, Cooper C . Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res. 2004; 19(2):330-7. DOI: 10.1359/JBMR.0301228. View

20.

Ettinger B, San Martin J, Crans G, Pavo I . Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004; 19(5):745-51. DOI: 10.1359/JBMR.040117. View